

Basic Science: (May 2006)

1. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu MN, Boone E, Haegeman G. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappa B gene expression by soy isoflavones does not require estrogenic activity [Abstract]. *Cancer Res* 2006; **66**: 4852–4862.
2. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, Charpin C, Jacquemier J, Birnbaum D. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. [Abstract]. *Cancer Res* 2006; **66**: 4636–4644.
3. Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration [Abstract]. *Cancer Res* 2006; **66**: 4725–4733.
4. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [Abstract]. *Cancer Res* 2006; **66**: 5104–5110.
5. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, Mueller SC. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells [Abstract]. *Exp Cell Res* 2006; **312**: 1240–1253.
6. Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer [Abstract]. *Cancer Epidemiol Biomark Prev* 2006; **15**: 961–966.
7. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer [Abstract]. *Mod Pathol* 2006; **19**: 617–621.
8. Chabottaux V, Sounni NE, Pennington CJ, English WR, van den Brule F, Blacher S, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Edwards DR, Foidart JM, Noel A. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases [Abstract]. *Cancer Res* 2006; **66**: 5165–5172.
9. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival [Abstract]. *Cancer Res* 2006; **66**: 5287–5294.
10. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells [Abstract]. *Mol Cell Biol* 2006; **26**: 3955–3965.
11. Cui XJ, Kim HJ, Kuitse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell migration [Abstract]. *Cancer Res* 2006; **66**: 5304–5313.
12. Deugnier MA, Faraldo MM, Teuliere J, Thiery JP, Medina D, Glukhova MA. Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-D beta cell line [Abstract]. *Dev Biol* 2006; **293**: 414–425.
13. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome [Abstract]. *Cancer Res* 2006; **66**: 5487–5494.
14. Espino PS, Li L, He SH, Yu J, Davie JR. Chromatin modification of the Trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway [Abstract]. *Cancer Res* 2006; **66**: 4610–4616.
15. Ewens A, Luo LQ, Berleth E, Alderfer J, Wollman R, Bin Hafeez B, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoinmunotherapy against breast cancer in mice [Abstract]. *Cancer Res* 2006; **66**: 5419–5426.

16. Fotovati A, Fujii T, Yamaguchi M, Kage M, Shirouzu K, Oie S, Basaki Y, Ono M, Yamana H, Kuwano M. 17 beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells [Abstract]. *Clin Cancer Res* 2006; **12**: 3010–3018.
17. Frank B, Hemminki K, Meindl A, Wappenschmidt B, Klaes R, Schmutzler RK, Untch M, Bugert P, Bartram CR, Burwinkel B. Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk [Abstract]. *Int J Cancer* 2006; **118**: 2505–2508.
18. Glaros S, Atanaskova N, Zhao CQ, Skafar DF, Reddy KB. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen [Abstract]. *Mol Endocrinol* 2006; **20**: 996–1008.
19. Gong YX, Sohn H, Xue L, Firestone GL, Bjeldanes LF. 3,3'-diindolylmethane is a novel mitochondrial H⁺-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells [Abstract]. *Cancer Res* 2006; **66**: 4880–4887.
20. Guo SQ, Lu J, Subramanian A, Sonenshein GE. Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in Her-2/neu-overexpressing breast cancer cells [Abstract]. *Cancer Res* 2006; **66**: 5322–5329.
21. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE, Ormandy CJ. Socs2 and Elf5 mediate prolactin-induced mammary gland development [Abstract]. *Mol Endocrinol* 2006; **20**: 1177–1187.
22. Hashimoto S, Hiroso M, Hashimoto A, Morishige M, Yamada A, Hosaka H, Akagi KI, Ogawa E, Oneyama C, Agatsuma T, Okada M, Kobayashi H, Wada H, Nakano H, Ikegami T, Nakagawa A, Sabe H. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. *Proc Natl Acad Sci USA* 2006; **103**: 7036–7041.
23. Hochreiter AE, Xiao HL, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer [Abstract]. *Clin Cancer Res* 2006; **12**: 3184–3192.
24. Joung KE, Min KN, An JY, Kim DK, Kong G, Sheen YY. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTWc-Neu mice [Abstract]. *Cancer Res* 2006; **66**: 5394–5402.
25. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I. BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells [Abstract]. *J Biol Chem* 2006; **281**: 14654–14662.
26. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, Isaacs JS, Bae I. BRCA1 plays a role in the hypoxic response by regulating HIF-1 alpha stability and by modulating vascular endothelial growth factor expression [Abstract]. *J Biol Chem* 2006; **281**: 13047–13056.
27. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y, Dewhirst MW, Fields TA, Casey PJ. The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis [Abstract]. *Proc Natl Acad Sci USA* 2006; **103**: 8173–8178.
28. Kristensen VN, Edvardsen H, Tsalenko A, Nordgardt SH, Sorlie T, Sharan R, Vailaya A, Ben-Dor A, Lonning PE, Lien S, Omholt S, Syvanen AC, Yakhini Z, Borresen-Dale AL. Genetic variation in putative regulatory loci controlling gene expression in breast cancer [Abstract]. *Proc Natl Acad Sci USA* 2006; **103**: 7735–7740.
29. Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G. Hypoxia inducible factor-1 alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response [Abstract]. *Int J Cancer* 2006; **118**: 2609–2616.
30. MacMahon B. Epidemiology and the causes of breast cancer [Abstract]. *Int J Cancer* 2006; **118**: 2373–2378.
31. Maskarinec G, Takata Y, Pagano I, Lurie G, Wilkens LR, Kolonel LN. Alcohol consumption and mammographic density in a multiethnic population [Abstract]. *Int J Cancer* 2006; **118**: 2579–2583.
32. Miller WR, Anderson TJ, Dixon JM, Saunders PTK. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment [Abstract]. *Br J Cancer* 2006; **94**: 1333–1338.
33. Nilsson UW, Dabrosin C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo [Abstract]. *Cancer Res* 2006; **66**: 4789–4794.
34. Paonessa F, Foti D, Costa V, Chiefari E, Brunetti G, Leone F, Luciano F, Wu F, Lee AS, Gulletta E, Fusco A, Brunetti A. Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer [Abstract]. *Cancer Res* 2006; **66**: 5085–5093.

35. Park BW, Kim KS, Heo MK, Yang WI, Kim IS, Kim JH, Kim GE, Lee KS. The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta 2 expression is the key event in breast cancer development [Abstract]. *J Surg Oncol* 2006; **93**: 504–510.
36. Pathak AP, Artemov D, Neeman M, Bhujwala ZM. Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype [Abstract]. *Cancer Res* 2006; **66**: 5151–5158.
37. Pedram A, Razandi M, Wallace DC, Levin ER. Functional estrogen receptors in the mitochondria of breast cancer cells [Abstract]. *Mol Biol Cell* 2006; **17**: 2125–2137.
38. Perez-Tenorio G, Berglund F, Merca AE, Norden-skjold B, Rutqvist LE, Skoog L, Stal O. Cytoplasmic p21(WAF1/CIP1) correlates with Akt activation and poor response to tamoxifen in breast cancer [Abstract]. *Int J Oncol* 2006; **28**: 1031–1042.
39. Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB. A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women [Abstract]. *Cancer Res* 2006; **66**: 5521–5525.
40. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis [Abstract]. *Cancer Res* 2006; **66**: 5278–5286.
41. Smid M, Wang YX, Klijn JGM, Sieuwerts AM, Zhang Y, Atkins D, Martens JWM, Foekens JA. Genes associated with breast cancer metastatic to bone [Abstract]. *J Clin Oncol* 2006; **24**: 2261–2267.
42. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism [Abstract]. *Cancer Res* 2006; **66**: 5504–5511.
43. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation [Abstract]. *Oncogene* 2006; **25**: 2931–2936.
44. Watermann DO, Tang YS, zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-beta 1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene [Abstract]. *Cancer Res* 2006; **66**: 4774–4780.
45. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu LH, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer [Abstract]. *Proc Natl Acad Sci USA* 2006; **103**: 7795–7800.
46. Xu Y, Yao LH, Li HX, Tao OY, Li JF, Wang TF, Fan ZQ, Lin BY, Lu YY, Larsson O, Xie YT. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status [Abstract]. *Breast Cancer Res Treat* 2006; **97**: 49–55.
47. Yin YJ, Katz V, Salah Z, Maoz M, Cohen I, Uziely B, Turm H, Grisaru-Granovsky S, Suzuki H, Bar-Shavit R. Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization [Abstract]. *Cancer Res* 2006; **66**: 5224–5233.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia